BACKGROUND: Laboratory tests to assess novel oral anticoagulants (NOACs) are under evaluation. Routine monitoring is unnecessary, but under special circumstances bioactivity assessment becomes crucial. We analyzed the effects of NOACs on coagulation tests and the availability of specific assays at different laboratories.
such as thrombin inhibitor dabigatran (Dabi) and activated factor X (Xa) inhibitor rivaroxaban (Riva), offer effective alternatives for anticoagulation (1, 2 ) . Whereas vitamin K antagonists (VKAs) have highly variable pharmacokinetics and pharmacodynamics and require monitoring with the international normalized ratio (INR) assay, those aspects of the NOACs are more predictable and routine monitoring is not necessary (3, 4 ) .
Occasionally, bioactivity assessment of the NOAC may be vital, e.g., in cases of severe bleeding or thrombotic complications, acute infection, emergency surgery, or suspected overdose. Typical plasma concentrations during treatment range from 50 to 400 g/L (ng/ mL); however, no therapeutic window per se exists (3, 4 ) . Some fatal and major bleeds have been associated with high plasma concentrations of Dabi, especially with renal impairment (5, 6 ) . The effect of NOACs has not been studied in many other coinciding clinical conditions with increased bleeding diathesis, e.g., anemia, thrombocytopenia, or liver failure (7, 8 ) .
Coagulation screening assays, including the prothrombin time (PT), INR, and activated partial thromboplastin time (APTT), are widely available. For measuring PT, both Owren and Quick methods are used, the former influenced only by coagulation factors II, VII, and X, instead of the complete extrinsic and common pathways. When spiked to plasma, Dabi dosedependently prolongs the APTT. The prolongation is nonlinear, however, and plateaus at high concentra-tions (4, 9 ) . The INR response is more linear, but not sensitive enough. Thrombin time (TT) is too sensitive at therapeutic concentrations but is a useful indicator of the presence of Dabi. A Dabi-calibrated TT performed on diluted samples is able to quantify Dabi linearly (9 -11 ) . Riva prolongs the APTT in a nonlinear manner but only modestly at trough concentrations (12 ) . INR responses vary widely depending on the thromboplastin assay reagent, but a calibrated anti-Xa assay appears to be a suitable method for determination of Riva concentration (13) (14) (15) (16) .
We aimed to assess the effects of NOACs on coagulation screening tests, as well as on more specific assays between different laboratories. This survey was conducted in conjunction with an international coagulation external quality assessment (EQA) round to examine the variety of reagents and the availability of more specific methods in a large number of laboratories. In addition to these spiked samples, we controlled some of the findings in clinical patient samples.
Materials and Methods

DABI AND RIVA SAMPLES AND METHODS
Lyophilized pooled normal human plasma samples spiked with Dabi (Aniara) at final concentrations of 120 and 300 g/L were delivered to 115 European laboratories (Poland 49, Finland 35, Lithuania 17, Latvia 9, Estonia 3, and Iceland 2) by the EQA organization Labquality in July 2011. Samples were kindly donated by Boehringer Ingelheim Finland. Laboratories were instructed to reconstitute the plasma with 1.0 mL distilled water, shake thoroughly, and incubate for 30 min at room temperature, mixing periodically, before analysis. Laboratories were then asked to use screening tests and more specific assays (such as TT) available on the two samples. Altogether 73 laboratories (63.5%) reported results; TT was reported by only 11 laboratories.
Lyophilized pooled normal human plasma samples spiked with Riva (Technoclone) at final concentrations of 60, 146, and 305 g/L were delivered to 38 laboratories (Finland 18, Norway 9, Ireland 5, Denmark 2, Sweden 2, Estonia 1, and Lithuania 1) by Labquality in January 2012. Samples were kindly donated by Bayer Schering Pharma. Laboratories were instructed to reconstitute the plasma with 1.0 mL distilled water, mix by rotating carefully avoiding foaming, and incubate for at least 10 min at room temperature before analysis. Laboratories were then asked to use the screening tests and more specific assays (such as anti-Xa) available on the 3 samples; 22 (57.9%) laboratories reported results. In addition, calibrators with Riva concentrations of 0, 15, 60, 100, and 150 g/L were sent to 18 Finnish laboratories for the local anti-Xa assay of Riva. Riva-calibrated anti-Xa results were reported by 8 laboratories.
The different reagents used by the participating laboratories are summarized in Table 1 . In total, 23 different coagulation analyzers from 8 different manufacturers were used. The effects of analyzers were not assessed in this survey.
To compare the differences between patient samples and spiked samples, we used clinical patient samples from Helsinki University Central Hospital. Ten samples from patients using Dabi and 10 using Riva were assessed with PT, APTT, and a test to determine the drug concentrations (Dabi-calibrated TT or Rivacalibrated anti-Xa). Nycotest PT® (Axis-Shield, Owren method) and Actin FSL® (Siemens Healthcare Diagnostics) reagents were used to measure PT and APTT, respectively. Patients used Dabi for either orthopedic surgery or atrial fibrillation indication; for Riva, all samples were from patients undergoing orthopedic surgery. Time intervals from drug ingestion to blood sampling were unknown.
STATISTICAL ANALYSIS
We analyzed the effects of the reagents with analysis of variance (ANOVA) and Student t-test. We used CVs to examine the variation between laboratories in different assays. Results are represented as box-plots, where bar lengths indicate the interquartile range (25th to 75th percentile). Outliers (circles in figures) were defined as values 1.5-3.0 bar lengths from the box edge, and extreme outliers (asterisks) as Ͼ3.0 bar lengths. In the APTT assay, because the baseline values were not known, we used the upper limit of the local reference interval reported by the laboratory to determine the prolongation of APTT at increasing drug concentrations. In comparisons of different reagents, results obtained with reagents used only in a single laboratory were excluded from statistical analysis. Statistical analyses were performed with Microsoft Excel® (2007) and IBM SPSS® (18.03) programs.
Results
Coagulation screening test INR and APTT results from different laboratories for Dabi and Riva samples are summarized in Table 2 .
DABI AND INR/PT
INR values for the plasma samples observed with Dabi (120 and 300 g/L) were reported by 71 laboratories. Thirteen different thromboplastin reagents were used (Table 1) . INR values were slightly increased in both plasma samples but were only modestly higher at 300 g/L Dabi. The interlaboratory agreement was not optimal (Table 2 ). There were differences in sensitivity between thromboplastin reagents (ANOVA P Ͻ 0.001). The mean relative change in INR between the two Dabi samples was 1.21 (range 1.11-1.55). The type of method used for INR analysis had an impact: the Quick method resulted in both higher INR levels and larger increase in INR with increasing Dabi concentration than the Owren method (P Ͻ 0.001) (Fig. 1) .
The PT in seconds was somewhat longer with the higher Dabi concentration, but only 17 laboratories reported results. The prolongation of PT was small; 21.3 s (range 13.1-38.8 s) and 27.5 s (range 15.7-50.2 s) with a wide variation (CV 36.4% and 39.0%, respectively).
DABI AND APTT
APTT values for the 2 plasma samples with Dabi (120 and 300 g/L) were reported by 72 laboratories. Nine different APTT reagents were used (Table 1) . APTT 
DABI IN CLINICAL PATIENT SAMPLES
The mean concentration of Dabi as measured by Dabicalibrated TT in 10 clinical patient plasma samples was 119 g/L (range 100 -135.5 g/L). For the patient samples, INR was mean 1.08 (range 0.96 -1.17), whereas for the spiked sample of 120 g/L with the same reagent (Nycotest PT), INR was slightly higher, mean 1.16 (P Ͻ 0.01) (Fig. 1) . For both clinical and spiked samples, the INR was within reference range. Mean APTT for the patient samples was 39.8 s (range 33-42.6 s), whereas in the spiked sample of 120 g/L with the same reagent (Actin FSL), APTT was higher, mean 54.2 s (P Ͻ 0.001) (Fig. 2) . This difference is clinically relevant, since in the patient sample group, APTT prolongation was clearly less pronounced, in 1 sample even being within local reference interval.
RIVA AND INR/PT
INR values were reported by 22 laboratories for the 3 plasma samples with Riva (60, 146, and 305 g/L). Five different thromboplastin reagents were used (Table 1) . INR values were only slightly influenced by Riva. The INR value of 1.9 was not reached by any of the labora- tories. The agreement between laboratories was relatively good, with low CVs (Table 2) . However, there were significant differences in INR responses between reagents (P Ͻ 0.005). The relative change in INR between the lowest and highest Riva concentrations was mean 1.25 (range 1.14 -1.43). The method (Quick vs Owren) had little effect on the result (Fig. 3) For the highest concentration of Riva, the PT exceeded the upper reference limit in all laboratories.
RIVA AND APTT
APTT values were reported by 22 laboratories. Four different reagents were used (Table 1) . APTT prolongation was dose dependent, but modest for the 3 samples (60, 146, and 305 g/L Riva). However, the increase seemed nonlinear (Fig. 4) . Again, there was large variation between laboratories (P Ͻ 0.001) ( Table 2 ). The reagent used had a distinct effect on the APTT: there was a small but significant difference in the magnitude of response to increasing concentrations of Riva between the different reagents (P Ͻ 0.05) (Fig. 4) .
RIVA AND ANTI-Xa CALIBRATED FOR RIVA
Eight laboratories reported anti-Xa (36% of the 22 laboratories reporting results). Two laboratories reported accurate concentration results for all the samples, whereas 6 underestimated the highest concentration, probably because the highest calibration sample concentration (150 g/L) was clearly too low for these samples (Table 2) . Two laboratories used anti-Xa reagents with exogenous antithrombin (reagent Berichrom Heparin, in Table 1 
Discussion
This survey aimed to assess the effect of NOACs Dabi and Riva on both routine anticoagulant assays and drug-specific assays in relation to a large number of methods and reagents in 10 European countries. Laboratory assessment of the degree of anticoagulation may be needed in special situations, and readily available screening assays are required. Therefore, laboratories should be aware of the drug-specific sensitivity of their own PT, INR, and APTT assays (17 ) . As expected, a wide variety of coagulation screening reagents were used: in total, 13 INR and 9 APTT reagents in numerous combinations with 23 different coagulometers. Here, only a few laboratories (15% and 36%) reported specific assay results on the Dabi and Riva rounds, respectively.
The routine anticoagulation test PT/INR is of limited value in measuring the anticoagulant effects of the NOACs. Here, the INR values varied widely between different reagents, especially with Dabi samples, in concordance with previous studies (11, 18 ) . Our new observation was that the Owren-method PT reagents were particularly insensitive to Dabi, and there was little variation (Fig. 1) . In addition, in our small group of clinical patients using Dabi, all had INR values in the reference range measured with the Owren method. In contrast, with the Quick-method reagents, the range was 3-fold even at the lower concentration of Dabi. Our data contradict the suggested INR levels of 1.5 (Owren) and 2.0 (Quick) for Dabi overdose screening (18 ) . Furthermore, point-of-care INR devices may in some cases provide falsely high readings when used with patients on Dabi (19 ) . With Riva samples, the INR value of 1.9 was not reached by any of the laboratories even at the highest concentration of 305 g/L. Neoplastin CI Plus® reagent (Diagnostica Stago), owing to its sensitivity, has been suggested to be suitable as a qualitative test reagent (13, 20 ) . According to this survey, that is currently of limited practical value, since of the laboratories reporting results in the Riva round, none used that reagent.
When assessing the effects of NOACs, the PT rather than the INR has been suggested, as the INR is calibrated for VKAs only. The differences between reagents are enlarged with thromboplastin reagents of high international sensitivity index (ISI) (16, 21 ) . The ISI values of the reagents in our study were fairly similar and close to 1.0 (according to the manufacturers, range 0.9 -1.3). The differences in PT results were slightly larger with increasing drug concentrations for both NOACs. Recently, there have been efforts to standardize PT methods by creating an ISI for Riva, analogous to the ISI for VKAs. However, this calibration applies only to the Quick method and is available in only a limited number of laboratories (21 ) . The INR/ PT, being widely available, is likely to be used to measure NOACs, despite not being optimal. Here, INR results were similarly inert between the clinical patient samples and in vitro samples with the low drug concentration. All the APTT reagents detected the presence and dose-dependence of Dabi well. The APTT was prolonged even at the lower concentration almost uniformly, but with a 2-fold variance between reagents. Of the most frequently used reagents, Actin FSL® (Siemens Healthcare Diagnostics) was one of the least responsive, whereas Stago PTT® (Stago) responded more vigorously (Fig. 2) . These reagent-related findings agree with those of Lindahl et al. (18 ) but are at odds with those of Douxfils et al. (10 ) . The APTT is recommended as an indicator test of the presence of Dabi because of its high sensitivity, a statement supported by the results from our spiked samples (17 ) . However, in patient samples, APTT was less sensitive than in spiked samples. Indeed, clinicians must exercise caution when using the APTT to assess the effects of Dabi, as APTT may be normal even at therapeutic concentrations (22 ) . The dose response is curvilinear and clearly affected by the clinical situation. The effect of Riva on the APTT was modest and nonlinear, in accord with previous studies (13 ) .
Specific assays were available in relatively few centers. TT results were provided by 11 laboratories (15%), but only 1 of them had the calibrated diluted TT assay available to measure the concentration with accurate results. Anti-Xa was able to measure the Riva concentration, when specifically calibrated, which is compatible with previous studies (16 ) . Generally, anti-Xa assays are readily available and widely used and can be relatively easily calibrated to accurately measure factor Xa inhibitor concentrations. Nonetheless, hospital laboratories are also validating suitable tests for detection of anticoagulant effects for routine use (11, 13, 15, 16, 18, 23 ) . Increased availability of calibrants and further EQA rounds are needed to help laboratories set up and maintain the specific assays.
When examining the results of our survey, the limitations of the sample materials should be recognized. Not being optimal, lyophilized plasma may reduce coagulation factor activities and prolong PT and APTT values compared with fresh plasma (24, 25 ) . However, the samples sent to different laboratories were produced in a similar standardized manner. Furthermore, currently the use of patient plasma rather than spiked normal plasma would be possible only in a limited number of laboratories, and with the NOACs, such material is still sparse. Thus, applying these data to clinical practice should be done with caution.
The samples from patients using NOACs differ somewhat from the spiked samples. At similar drug concentrations, the APTT was less sensitive to Dabi in patient samples than in spiked samples, a fact bearing clinical significance as APTT does not necessarily alert for the presence of Dabi. As significant variation between PT and APTT reagents was observed with in vitro spiked normal plasma, the variation between patient samples is also likely to exceed this amount in vivo. The clinical situations with varying coagulation status, i.e., renal or liver impairment, infection, surgery, bleeding, or thrombosis, modify both the results of global coagulation assays and the efficacy of NOACs, further complicating the interpretation. Unfortunately, there are still limited data on laboratory monitoring of patients with bleeds (6, 26 ) . As routine monitoring is not performed, experience of the plasma concentrations of the NOACs at desired or sub-/supratherapeutic doses will not accumulate. Most often, the knowledge on NOAC concentrations is needed suddenly during on-call hours. In the absence of specific antidotes, nonspecific bypassing agents (i.e., prothrombin complex concentrates and recombinant FVIIa) may provide clinical benefit (27, 28 ) . However, these agents influence both PT and APTT, which may not reflect the clinical efficacy of the reversal, further complicating the interpretation. Instead, calibrated TT and anti-Xa assays offer specific and accurate concentration monitoring under special situations.
In conclusion, routine anticoagulation assays PT, INR, and APTT are highly reagent dependent and do not provide accurate measurement of the activity of NOACs. However, each laboratory should test the sensitivity of their assays to NOACs. We also believe that laboratories need to validate calibrated specific assays more widely. Therefore, EQA rounds for NOACs must be established to standardize and harmonize laboratory practices, as an increasing number of laboratories will apply these tests for clinical practice.
